



28 June 2010

NEWS RELEASE

Innomech teams up with biotechnology company for end-of-line test systems

One of the world's leading biotechnology groups has appointed GB Innomech (Innomech) to develop a sophisticated, automated end-of-line testing system for a new drug delivery pen. Innomech was first asked to advise on the feasibility of automating an existing quality control process for the multi-dose, dial-a-dose injection pen before being appointed to design and build two machines.

Innomech's new easy-to-use system incorporates calibrated measuring devices to check and record over 20 parameters on four key areas of the pen while simulating use of the assembled, multi-part injection device. For example, the system measures the forces required to fire the trigger or adjust the dose control knob before comparing them against agreed tolerances to confirm products comply fully with the required specification. The fully automated test routine takes approximately 30 seconds to complete.

The testing machine also provides detailed feedback for statistical analysis and process improvement; it can be easily reconfigured to test different variants of the same pen and requires minimal operator training. The system has been provided with a documentation package for validation, for use in pharmaceutical manufacturing environments.

"Innomech works with many major pharmaceutical companies across the world but this is our first large-scale project for this biotechnology company. Our project managers and engineers teamed up with the biotech's in-house resource in California to develop the system specification based on critical performance parameters and perceived risks in the production process for the pen. Having identified these challenges, the two comprehensive end-of-line testing machines were then designed, built and delivered on a jointly agreed schedule," said Steve Robertson, managing director of Innomech.

... continued

Notes to Editors

About GB Innomech

GB Innomech (Innomech) specialises in automating highly complex and labour-intensive manufacturing processes to maximise outputs, improve product quality and boost business performance. The company works with major international manufacturers in sectors such as pharmaceuticals, medical devices and environmental, as well as earlier-stage businesses looking to bring breakthrough technologies or products to market.

Innomech has a growing market reputation for solving the toughest of manufacturing problems by the early identification and management of risk, often cross-fertilising technologies and techniques from a range of industry sectors. All projects from initial feasibility studies through to building production-scale machines are conducted to high specification pharmaceutical industry standards and are designed to comply with GAMP5, FDA and other international standards.

The company was founded in 1990, is based at The Innovation Centre in Witchford, north of Cambridge and was awarded The Queen's Award for Enterprise 2009 to recognise its sustained growth in international markets.

For additional information please visit or contact:

- www.innomech.co.uk
- Press enquiries to Simon McKay on +44 (0)1353 741075 or email to simonmckay@innomech.co.uk
- All other enquiries to Steve Robertson at Innomech on +44 (0)1353 667394

Photographs

A print quality JPEG of the image below has been sent as a separate file attached to the original email or is also available on request from Simon McKay (details above):



Innomech was appointed by a California-based biotech group to design and build two end-of-line testing systems for a new multi-dose, dial-a-dose drug delivery pen. The easy-to-use system requires minimal operator training to check and record over 20 parameters on the assembled pen.